Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 6Phase 3 5Phase 1/2 4

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 14Other hematologic neoplasm 5

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5Recurrence 1

Interventions

Cytarabine 166Cyclophosphamide 110Daunorubicin 88Methotrexate 83Etoposide 66Vincristine 63Mercaptopurine 55Rituximab 54Dexamethasone 54venetoclax 50fludarabine 47Doxorubicin 46Azacitidine 46Idarubicin 45Asparaginase 42Imatinib Mesylate 41Prednisone 39pegaspargase 37Thioguanine 36Radiotherapy 35Mitoxantrone 35Busulfan 31Peripheral Blood Stem Cell Transplantation 25Leucovorin 25Bendamustine Hydrochloride 25fludarabine phosphate 24Filgrastim 24obinutuzumab 23nilotinib 23Granulocyte Colony-Stimulating Factor 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × zanubrutinib × Other hematologic neoplasm × Clear all
NCT07277231 2026-06-03

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

BeOne Medicines

Phase 3 Recruiting
500 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06073821 2026-06-01

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

BeOne Medicines

Phase 3 Active not recruiting
652 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03336333 2026-03-09

SEQUOIA

BeOne Medicines

Phase 3 Active not recruiting
590 enrolled 12 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07321652 2026-01-07

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Alliance for Clinical Trials in Oncology

Phase 3 Not yet recruiting
466 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03734016 2025-03-30

ALPINE

BeiGene

Phase 3 Completed
652 enrolled 27 charts 1 FDA
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡